Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Sotorasib is a selective irreversible inhibitor of the G12C-activated KRAS oncogene, present in approximately 13% of non–small-cell lung cancers. In a single-group, phase 2 trial involving 126 patients with previously treated KRAS p.G12C–mutated NSCLC, 37% had a response (median duration, 11 months)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-06, Vol.384 (25), p.2371-2381
Hauptverfasser:	Skoulidis, Ferdinandos, Li, Bob T, Dy, Grace K, Price, Timothy J, Falchook, Gerald S, Wolf, Jürgen, Italiano, Antoine, Schuler, Martin, Borghaei, Hossein, Barlesi, Fabrice, Kato, Terufumi, Curioni-Fontecedro, Alessandra, Sacher, Adrian, Spira, Alexander, Ramalingam, Suresh S, Takahashi, Toshiaki, Besse, Benjamin, Anderson, Abraham, Ang, Agnes, Tran, Qui, Mather, Omar, Henary, Haby, Ngarmchamnanrith, Gataree, Friberg, Gregory, Velcheti, Vamsidhar, Govindan, Ramaswamy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antitumor activity Apoptosis B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - metabolism Biomarkers Biomarkers - blood Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy Confidence intervals Disease control Dosage Female Genetics Hematology Humans Immunotherapy K-Ras protein Lung Cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Medical prognosis Metastasis Middle Aged Mutation Non-small cell lung carcinoma Oncology Oral administration Patients PD-1 protein PD-L1 protein Piperazines - adverse effects Piperazines - therapeutic use Progression-Free Survival Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors Pyridines - adverse effects Pyridines - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Small cell lung carcinoma Solid tumors Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Sotorasib is a selective irreversible inhibitor of the G12C-activated KRAS oncogene, present in approximately 13% of non–small-cell lung cancers. In a single-group, phase 2 trial involving 126 patients with previously treated KRAS p.G12C–mutated NSCLC, 37% had a response (median duration, 11 months). One fifth of patients had grade 3 toxic effects, mainly liver-enzyme abnormalities and diarrhea.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2103695